Sugi Predict

Sugi Predict / Compounds / SCHEMBL316417

SCHEMBL316417

SCHEMBL316417

FC1(F)Oc2ccc(Br)cc2OC1(F)F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 3/20 0.50
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KIF11 P52732 1/20 0.40
▸ HTR2C P28335 1/20 0.34
▸ BACE1 P56817 5/20 0.34
▸ CA12 O43570 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CTNNB1 P35222 1/20 0.31
▸ WNT3A P56704 1/20 0.31
▸ CYP2A6 P11509 1/20 0.30
▸ NOTUM Q6P988 1/20 0.30
▸ PIK3CA P42336 1/20 0.30
▸ PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31085202 1.00 AHR (0.50) AHRLMNAMAPTHTTBLM
SCHEMBL12046 0.86 AHR (0.50) AHRLMNAMAPTHTTBLM
SCHEMBL9349990 0.86 AHR (0.42) AHRLMNAMAPTHTTBLM
SCHEMBL29457677 0.77 TSHR (0.56) AHRLMNAMAPTHTTBLM
SCHEMBL361525 0.77 TSHR (0.56) AHRLMNAMAPTHTTBLM
SCHEMBL25446352 0.77 AHR (0.50) AHRLMNAMAPTHTTBLM
SCHEMBL6601303 0.77 AHR (0.50) AHRLMNAMAPTHTTBLM
SCHEMBL9875356 0.77 AHR (0.40) AHRLMNAMAPTHTTBLM
SCHEMBL29107151 0.77 AHR (0.40) AHRLMNAMAPTHTTBLM
SCHEMBL8760137 0.75 AHR (0.48) AHRKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 — — CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
EP-1776011-B1 FUNGICIDAL COMPOSITION CONTAINING AN ACID AMIDE DERIVATIVE ISHIHARA SANGYO KAISHA (JP) 2012-03-21 — — EP disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-8093241-B2 Acid amide derivatives, process for their production and pesticides containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 2012-01-10 — — US disclosed
US-8039420-B2 Fungicidal composition containing acid amide derivative ISHIHARA SANGYO KAISHA, LTD. (JP) 2011-10-18 — — US disclosed
US-6569881-B1 For mixture with polyether antibiotics or synthetically prepared coccidiosis agents BAYER AKTIENGESELLSCHAFT (DE) 2003-05-27 — — US disclosed
WO-2003002115-A2 SUBSTITUTED BENZIMIDAZOLES FOR CONTROLLING ENDOPARASITES BAYER AKTIENGESELLSCHAFT (DE) 2003-01-09 — — WO disclosed
CN-1349529-A Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa BAYER AG (DE) 2002-05-15 — — CN disclosed
EP-1177191-A1 SUBSTITUTED BENZIMIDAZOLE, THE PRODUCTION THEREOF AND THE USE THEREOF AS MEANS AGAINST PARASITIC PROTOZOA Bayer Aktiengesellschaft (DE) 2002-02-06 — — EP disclosed
US-6232475-B1 REACTING A SUBSTITUTED BROMOBENZENE WITH N-VINYLIMIDE; CATALYTIC HYDROGENATION BAYER AKTIENGESELLSCHAFT (DE) 2001-05-15 — — US disclosed
EP-1097154-A1 SUBSTITUTED BENZIMIDAZOLES, PRODUCTION AND USE THEREOF AS AGENTS FOR COMBATING PARASITIC PROTOZOAS Bayer Aktiengesellschaft (DE) 2001-05-09 — — EP disclosed
WO-2000068225-A1 SUBSTITUTED BENZIMIDAZOLE, THE PRODUCTION THEREOF AND THE USE THEREOF AS MEANS AGAINST PARASITIC PROTOZOA BAYER AKTIENGESELLSCHAFT (DE) 2000-11-16 — — WO disclosed
EP-1013637-A2 Process for the preparation of fluor containing phenethylamines and fluor containing beta-iminovinyl- and beta-iminoethylphenyl compounds Bayer Aktiengesellschaft (DE) 2000-06-28 — — EP disclosed
WO-2000004022-A1 SUBSTITUTED BENZIMIDAZOLES, PRODUCTION AND USE THEREOF AS AGENTS FOR COMBATING PARASITIC PROTOZOAS BAYER AKTIENGESELLSCHAFT (DE) 2000-01-27 — — WO disclosed
US-5283378-A Process for the dechlorination and/or debromination of fluorine-and chlorine- and/or bromine-containing aromatic compounds BAYER AKTIENGESELLSCHAFT (DE) 1994-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 AHR 1940/4885LMNA 2387/4885MAPT 3533/4885
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 AHR 2702/4885LMNA 4126/4885MAPT 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.